Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.

Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, Wilensky RL, O'Neill WW; CONTRAST Investigators.

JAMA. 2003 Nov 5;290(17):2284-91.

PMID:
14600187
2.

Fenoldopam for the prevention of contrast-induced nephropathy (CIN)-do we need more trials? A meta-analysis.

Naeem M, McEnteggart GE, Murphy TP, Prince E, Ahn S, Soares G.

Clin Imaging. 2015 Sep-Oct;39(5):759-64. doi: 10.1016/j.clinimag.2015.02.003. Epub 2015 Feb 12. Review.

PMID:
25709111
3.

Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy: a review.

Walker PD, Brokering KL, Theobald JC.

Pharmacotherapy. 2003 Dec;23(12):1617-26. Review.

PMID:
14695041
4.
5.

[Fenoldopam: potential clinical applications in heart surgery].

Shorten GD.

Rev Esp Anestesiol Reanim. 2001 Dec;48(10):487-91. Review. Spanish.

PMID:
11792308
6.

Prophylaxis strategies for contrast-induced nephropathy.

Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network.

JAMA. 2006 Jun 21;295(23):2765-79. Review.

PMID:
16788132
7.

Radiocontrast-induced acute renal failure: allocations and outcomes.

Mehran R, Ashby DT.

Rev Cardiovasc Med. 2001;2 Suppl 1:S9-13. Review.

PMID:
12439362
8.

Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis.

Landoni G, Biondi-Zoccai GG, Marino G, Bove T, Fochi O, Maj G, CalabrĂ² MG, Sheiban I, Tumlin JA, Ranucci M, Zangrillo A.

J Cardiothorac Vasc Anesth. 2008 Feb;22(1):27-33. doi: 10.1053/j.jvca.2007.07.015. Epub 2007 Nov 7. Review.

PMID:
18249327
9.

Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention.

Mathur VS.

Rev Cardiovasc Med. 2001;2 Suppl 1:S4-8. Review.

PMID:
12439361
10.

Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography.

Manske CL, Sprafka JM, Strony JT, Wang Y.

Am J Med. 1990 Nov;89(5):615-20. Review.

PMID:
2239981
11.

Fenoldopam in the prevention of contrast media-induced acute renal failure.

Chu VL, Cheng JW.

Ann Pharmacother. 2001 Oct;35(10):1278-82. Review. Erratum in: Ann Pharmacother 2002 Feb;36(2):346. Ann Pharmacother 2001 Dec;35(12):1677.

PMID:
11675860
12.

Radiocontrast-induced acute renal failure.

Weisbord SD, Palevsky PM.

J Intensive Care Med. 2005 Mar-Apr;20(2):63-75. Review.

PMID:
15855219
13.

Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.

Mintz EP, Gruberg L.

Expert Opin Pharmacother. 2003 May;4(5):639-52. Review.

PMID:
12739990
14.

N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis.

Liu R, Nair D, Ix J, Moore DH, Bent S.

J Gen Intern Med. 2005 Feb;20(2):193-200. Review.

15.

[Is dialysis efficient in the prevention of ionic contrast agent-induced nephropathy?].

Karie S, Launay-Vacher V, Izzedine H, Deray G.

Presse Med. 2005 Jun 18;34(11):803-8. Review. French.

PMID:
16097384
16.

[Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost].

Yano T.

Yakugaku Zasshi. 2008 Jul;128(7):1023-9. Review. Japanese.

17.

Does prophylactic haemodialysis protect kidney function after angiography?

Tepel M.

Nephrol Dial Transplant. 2008 May;23(5):1473-5. doi: 10.1093/ndt/gfn019. Epub 2008 Jan 28. Review. No abstract available.

PMID:
18227136
18.

Preventing contrast-induced nephropathy: problems, challenges and future directions.

Solomon R.

BMC Med. 2009 May 13;7:24. doi: 10.1186/1741-7015-7-24. Review.

19.

Supplemental Content

Support Center